WO2010139953A1 - Compounds - Google Patents

Compounds Download PDF

Info

Publication number
WO2010139953A1
WO2010139953A1 PCT/GB2010/001092 GB2010001092W WO2010139953A1 WO 2010139953 A1 WO2010139953 A1 WO 2010139953A1 GB 2010001092 W GB2010001092 W GB 2010001092W WO 2010139953 A1 WO2010139953 A1 WO 2010139953A1
Authority
WO
WIPO (PCT)
Prior art keywords
optionally substituted
benzyl
oxo
chloro
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB2010/001092
Other languages
English (en)
French (fr)
Inventor
Richard John Hamlyn
David Madge
Mushtaq Mulla
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Xention Ltd
Original Assignee
Xention Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xention Ltd filed Critical Xention Ltd
Priority to JP2012513673A priority Critical patent/JP5684800B2/ja
Priority to EP10722754.8A priority patent/EP2438044B1/en
Publication of WO2010139953A1 publication Critical patent/WO2010139953A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/46—Iso-indoles; Hydrogenated iso-indoles with an oxygen atom in position 1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/24—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Definitions

  • KvI.3 channel blockers have been reported for the management of autoimmune disorders. These include the iminodihydroquinolines WINl 73173 and CP339818 (Nguyen et al, 1996), the benzhydryl piperidine UK-78,282 (Hanson et al 1999), correolide (Felix et al., 1999), cyclohexyl-substituted benzamide PAC (US-06194458, WO0025774), sulfamidebenzamidoindane (US-06083986), Khellinone (Baell et al, 2004), dichloropenylpyrazolopyrimidine (WO-00140231) and psoralens (Wulff et al, 1998., Vennekamp et al, 2004, Schmitz et al, 2005).
  • Substituted arylsulfonamides have been reported widely to be useful ligands for intervention in a number of therapeurtic areas, these range from inhibitors of 11-beta- hydroxysteroid dehydrogenase typel, for the treatment and prevention of hyperglycemia in diseases such as type-2 diabetes (WO2004065351), inhibitors of mitotic kinesins as effective anti cancer agents (WO2007056078), inhibitors of Factor Xa useful in the treatment of arterial and venous thrombotic occlusive disorders, inflammation, cancer and neurodegenerative diseases (WO96/40100), inhibitors of BACE as an effective means for treating and preventing Alzheimer's and related diseases caused by the production of beta-amyloid (WO2005/030709).
  • R 2 is selected from Imidazole, Pyrazole, or
  • Solvent [MeCN-H 2 O/0.1% HCO 2 H], 5-95% gradient 6min, 95% 3min; Column: Phenomenex Gemini 50 x 4.6 mm i.d. , Cl 8 reverse phase; Flow rate: lmL/min unless otherwise indicated.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
PCT/GB2010/001092 2009-06-04 2010-06-04 Compounds Ceased WO2010139953A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2012513673A JP5684800B2 (ja) 2009-06-04 2010-06-04 化合物
EP10722754.8A EP2438044B1 (en) 2009-06-04 2010-06-04 Compounds

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0909671.0 2009-06-04
GBGB0909671.0A GB0909671D0 (en) 2009-06-04 2009-06-04 Compounds

Publications (1)

Publication Number Publication Date
WO2010139953A1 true WO2010139953A1 (en) 2010-12-09

Family

ID=40936942

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2010/001092 Ceased WO2010139953A1 (en) 2009-06-04 2010-06-04 Compounds

Country Status (5)

Country Link
US (1) US8399481B2 (enExample)
EP (1) EP2438044B1 (enExample)
JP (1) JP5684800B2 (enExample)
GB (1) GB0909671D0 (enExample)
WO (1) WO2010139953A1 (enExample)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2714718A4 (en) * 2011-05-24 2015-01-14 Symic Biomedical Inc HYALURONIC ACID BINDING SYNTHETIC PEPTIDOGLYCANES, THEIR PREPARATION AND METHOD FOR THEIR USE
US9200039B2 (en) 2013-03-15 2015-12-01 Symic Ip, Llc Extracellular matrix-binding synthetic peptidoglycans
US9512192B2 (en) 2008-03-27 2016-12-06 Purdue Research Foundation Collagen-binding synthetic peptidoglycans, preparation, and methods of use
WO2018010142A1 (en) * 2016-07-14 2018-01-18 Shanghai Meton Pharmaceutical Co., Ltd Iso-citrate dehydrogenase (idh) inhibitor
US10772931B2 (en) 2014-04-25 2020-09-15 Purdue Research Foundation Collagen binding synthetic peptidoglycans for treatment of endothelial dysfunction
WO2021068698A1 (en) 2019-10-12 2021-04-15 Shanghai Meton Pharmaceutical Co., Ltd Iso-citrate dehydrogenase (idh) inhibitor
US11529424B2 (en) 2017-07-07 2022-12-20 Symic Holdings, Inc. Synthetic bioconjugates

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0909672D0 (en) * 2009-06-04 2009-07-22 Xention Discovery Ltd Compounds
ES2873505T3 (es) * 2016-10-25 2021-11-03 Borealis Ag Composición de polipropileno heterofásico con propiedades ópticas y mecánicas mejoradas

Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996040100A1 (en) 1995-06-07 1996-12-19 3-Dimensional Pharmaceuticals, Inc. ARYLSULFONYLAMINOBENZENE DERIVATIVES AND THE USE THEREOF AS FACTOR Xa INHIBITORS
WO2000025774A1 (en) 1998-10-30 2000-05-11 Merck & Co., Inc. Benzamide potassium channel inhibitors
US6077680A (en) 1996-11-27 2000-06-20 The University Of Florida ShK toxin compositions and methods of use
US6083986A (en) 1996-07-26 2000-07-04 Icagen, Inc. Potassium channel inhibitors
WO2001040231A1 (en) 1999-12-06 2001-06-07 Bristol-Myers Squibb Company Heterocyclic dihydropyrimidines as potassium channel inhibitors
US6300342B1 (en) 1997-06-26 2001-10-09 Boehringer Ingelheim Pharm Kg Antithrombotic phenylalkyl derivatives
WO2003082205A2 (en) 2002-03-27 2003-10-09 Smithkline Beecham Corporation Compounds and methods
WO2004065351A1 (en) 2003-01-24 2004-08-05 Novartis Ag Amide derivatives and their use as inhibitors of 11-beta-hydroxysteroid dehydrogenase type 1
WO2005030709A1 (en) 2003-10-01 2005-04-07 Lg Life Sciences Ltd. Novel sulfone amide derivatives capable of inhibiting bace
WO2007024944A1 (en) 2005-08-25 2007-03-01 Schering Corporation Imidazole derivatives as functionally selective alpha2c adrenoreceptor agonists
WO2007056078A2 (en) 2005-11-02 2007-05-18 Cytokinetics, Inc. Certain chemical entities, compositions, and methods
WO2007109211A2 (en) * 2006-03-17 2007-09-27 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services 1-oxo-isoindoline compounds for the treatment of spinal muscular atrophy and other uses
WO2007110171A1 (de) 2006-03-27 2007-10-04 Bayer Healthcare Ag Substituierte n-benzyl-n-phenylbenzolsulfonamide zur behandlung von virusinfektionen
WO2008038053A1 (en) 2006-09-29 2008-04-03 Lectus Therapeutics Limited Ion channel modulators & uses thereof
WO2008113760A2 (en) 2007-03-16 2008-09-25 Boehringer Ingelheim International Gmbh Arylsulphonyglycine derivatives as suppressors of the interaction of glycogen phosphorylase a with the gl subunit of glycogen-associated protein phosphatase 1 (ppl) for the treatment of metabolic disorders, particulary diabetes

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1856477A (zh) * 2003-09-23 2006-11-01 默克公司 异喹啉钾通道抑制剂
CA2571881A1 (en) * 2004-06-22 2006-01-26 Andreas P. Termin Heterocyclic derivatives for modulation of calcium channels
US20100160304A1 (en) 2005-01-19 2010-06-24 Dainippon Sumitomo Pharma Co., Ltd Aromatic sulfone compound as aldosterone receptor modulator
GB0710844D0 (en) 2007-06-06 2007-07-18 Lectus Therapeutics Ltd Potassium ion channel modulators & uses thereof
GB0815784D0 (en) * 2008-08-29 2008-10-08 Xention Ltd Novel potassium channel blockers
GB0815782D0 (en) * 2008-08-29 2008-10-08 Xention Ltd Novel potassium channel blockers
GB0815781D0 (en) * 2008-08-29 2008-10-08 Xention Ltd Novel potassium channel blockers
GB0909672D0 (en) * 2009-06-04 2009-07-22 Xention Discovery Ltd Compounds

Patent Citations (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996040100A1 (en) 1995-06-07 1996-12-19 3-Dimensional Pharmaceuticals, Inc. ARYLSULFONYLAMINOBENZENE DERIVATIVES AND THE USE THEREOF AS FACTOR Xa INHIBITORS
US6083986A (en) 1996-07-26 2000-07-04 Icagen, Inc. Potassium channel inhibitors
US6077680A (en) 1996-11-27 2000-06-20 The University Of Florida ShK toxin compositions and methods of use
US6300342B1 (en) 1997-06-26 2001-10-09 Boehringer Ingelheim Pharm Kg Antithrombotic phenylalkyl derivatives
WO2000025774A1 (en) 1998-10-30 2000-05-11 Merck & Co., Inc. Benzamide potassium channel inhibitors
US6194458B1 (en) 1998-10-30 2001-02-27 Merck & Co., Inc. Benzamide potassium channel inhibitors
WO2001040231A1 (en) 1999-12-06 2001-06-07 Bristol-Myers Squibb Company Heterocyclic dihydropyrimidines as potassium channel inhibitors
WO2003082205A2 (en) 2002-03-27 2003-10-09 Smithkline Beecham Corporation Compounds and methods
WO2004065351A1 (en) 2003-01-24 2004-08-05 Novartis Ag Amide derivatives and their use as inhibitors of 11-beta-hydroxysteroid dehydrogenase type 1
WO2005030709A1 (en) 2003-10-01 2005-04-07 Lg Life Sciences Ltd. Novel sulfone amide derivatives capable of inhibiting bace
WO2007024944A1 (en) 2005-08-25 2007-03-01 Schering Corporation Imidazole derivatives as functionally selective alpha2c adrenoreceptor agonists
WO2007056078A2 (en) 2005-11-02 2007-05-18 Cytokinetics, Inc. Certain chemical entities, compositions, and methods
WO2007109211A2 (en) * 2006-03-17 2007-09-27 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services 1-oxo-isoindoline compounds for the treatment of spinal muscular atrophy and other uses
WO2007110171A1 (de) 2006-03-27 2007-10-04 Bayer Healthcare Ag Substituierte n-benzyl-n-phenylbenzolsulfonamide zur behandlung von virusinfektionen
WO2008038053A1 (en) 2006-09-29 2008-04-03 Lectus Therapeutics Limited Ion channel modulators & uses thereof
WO2008113760A2 (en) 2007-03-16 2008-09-25 Boehringer Ingelheim International Gmbh Arylsulphonyglycine derivatives as suppressors of the interaction of glycogen phosphorylase a with the gl subunit of glycogen-associated protein phosphatase 1 (ppl) for the treatment of metabolic disorders, particulary diabetes

Non-Patent Citations (31)

* Cited by examiner, † Cited by third party
Title
ARMSTRONG; HILLE: "Voltage-gated ion channels and electrical excitability", NEURON, vol. 20, 1998, pages 371 - 380
BAELL JB ET AL.: "Khellinone Derivatives as Blockers of he Voltage-Gated Potassium Channel Kvl.3: Synthesis and Immunosuppressive Activity", J. MED. CHEM., vol. 47, 2004, pages 2326 - 2336, XP003026589, DOI: doi:10.1021/JM030523S
BEETON C; BARBARIA J; GIRAUD P; DEVAUX J; BENOLIEL A; GOLA M; SABATIER JM; BERNARD D; CREST M; BERAUD E: "Selective blocking of voltage-gated K+ channel improves experimental autoimmune encephalomyelitis and inhibits T cell activation", J. IMMUNOL., vol. 166, 2001, pages 936 - 944, XP003008618
BEETON C; PENNINGTON MW; WULFF H; SINGH S; NUGENT D; CROSSLEY G; KHAYTIN I; CALABRESI PA; CHEN CY; GUTMAN GA: "Targeting effector memory T cells with a selective peptide inhibitor of Kvl.3 channels for therapy of autoimmune diseases", MOL PHARMACOL., vol. 67, no. 4, 2005, pages 1369 - 81
BEETON ET AL.: "Kvl.3 channels are a therapeutic target for T cell-mediated autoimmune diseases", PROCEEDS OF THE NATIONAL ACADEMY OF SCIENCES, vol. 46, no. 103, 2006, pages 17414 - 17419
BRENDEL; PEUKERT: "Blockers of the Kvl.5 Channel for the Treatment of Atrial Arrhythmias", EXPERT OPINION IN THERAPEUTIC PATENTS, vol. 12, no. 11, 2002, pages 1589 - 1598, XP002537874, DOI: doi:10.1517/13543776.12.11.1589
CAHALAN MD; CHANDY KG: "Ion Channels in the Immune System as Targets for Immunosuppression", CURRENT OPINION IN BIOTECHNOLOGY, vol. 8, 1997, pages 749 - 756
CHANDY KG; WULFF H; BEETON C; PENNINGTON M; GUTMAN G; CAHALAN M: "K+ channels as targets for specific immunomodulation", TIPS, vol. 25, no. 5, 2004, pages 280 - 289, XP004505649, DOI: doi:10.1016/j.tips.2003.11.003
FELIX JP ET AL.: "Identification and Biochemical Characterization of a Novel Norterpene Inhibitor of the Human Lymphocyte Voltage-Gated Potassium Channel, Kvl.3", BIOCHEMISTRY, vol. 38, no. 16, 1999, pages 4922 - 4930
FORD ET AL.: "Potassium Channels: Gene Family, Therapeutic Relevance, High-Throughput Screening Technologies and Drug Discovery", PROG DRUG RES, vol. 58, 2002, pages 133 - 168, XP008113929
GARCIA ET AL.: "Purification and characterisation of three inhibitors of voltage dependent K+ channels from Leiurus quinquesttriatus var. hebraeus", BIOCHEMISTRY, vol. 33, 1994, pages 6834 - 6839
GARCIA ET AL.: "Purification, characterisation and biosynthesis of margatoxin, a component of Centruroides maragritatus venom that selectively inhibits voltage-gated potassium channels", J. BIOL. CHEM., vol. 268, 1993, pages 18866 - 1887
GUTMAN GA ET AL.: "International Union of Pharmacology. XLI. Compendium of voltage-gated ion channels: potassium channels", PHARMACOL REV., vol. 55, no. 4, November 2003 (2003-11-01), pages 583 - 6
HANSON DC ET AL.: "UK-78,282, a Novel Piperidine Compound That Potently Blocks the Kvl.3 Voltage-Gated Potassium Channel and Inhibits Human T Cell Activation", BR. J. PHARMACOL., vol. 126, 1999, pages 1707 - 1716, XP008091174, DOI: doi:10.1038/sj.bjp.0702480
HERBERT: "General principles of the structure of ion channels", AM. J. MED, vol. 104, 1998, pages 87 - 98, XP000891478, DOI: doi:10.1016/S0002-9343(97)00358-6
KOO GC; BLAKE JT; SHAH K; STARUCH MJ; DUMONT F; WUNDERLER DL; SANCHEZ M; MCMANUS OB; SIRONTINA-MEISHER A; FISCHER P: "Correolide and derivatives are novel immunosuppressants blocking the lymphocyte Kvl.3 potassium channels", CELL. IMMUNOL., vol. 197, 1999, pages 99 - 107
KOSHCHAK ET AL.: "Subunit composition of brain voltage-gated potassium channels determined by hongotoxin-1, a novel peptide derived from Centruroides limbatus venom", J. BIOL. CHEM., vol. 273, 1998, pages 2639 - 2644, XP002109758, DOI: doi:10.1074/jbc.273.5.2639
MOUHAT ET AL.: "K+ channel types targeted by synthetic OSK1, a toxin from Orthochirus scrobiculosus scorpion venom", BIOCHEM. J., vol. 385, 2005, pages 95 - 104, XP002352829, DOI: doi:10.1042/BJ20041379
NGUYEN A ET AL.: "Novel Nonpeptide Agents Potently Block the C-Type Inactivated Conformation of Kvl.3 and Suppress T Cell Activation", MOL. PHARMACOL., vol. 50, 1996, pages 1672 - 1679, XP008105165
PANYI G; VARGA Z; GASPAR R: "Abstract Ion channels and lymphocyte activation", IMMUNOLOGY LETT., vol. 92, 2004, pages 55 - 66, XP002464267, DOI: doi:10.1016/j.imlet.2003.11.020
PENNINGTON ET AL.: "Identification of there separate binding sites on Shk toxin, a potent inhibitor of voltage dependent potassium channels in human T-lymphocytes and rat brain", BIOCHEM. BIOPHYS. RES. COMMUN., vol. 219, 1996, pages 696 - 701, XP002061813, DOI: doi:10.1006/bbrc.1996.0297
PENNINGTON ET AL.: "ShK-Dap22, a potent Kvl.3-specific immunosuppressive polypeptide", J. BIOL. CHEM., vol. 273, 1998, pages 32697 - 35707
PETER ET AL.: "Effect of toxins Pi2 and Pi3 on human T Lymphocyte kvl.3 channels: the role of Glu7 and Lys24", J. MEMBR. BIOL., vol. 179, 2001, pages 13 - 25
PRICE MJ; LEE SC; DEUTSCH C: "Charybdotoxin inhibits proliferation and interleukin-2 production of human peripheral blood lymphocytes", PROC. NATL. ACAD. SCI., vol. 86, 1989, pages 10171 - 10175
SANDS ET AL.: "Charabydotoxin blocks voltage-gated K+ channels in human and murine T lymphocytes", J. GEN- PHYSIOL., vol. 93, 1989, pages 10061 - 1074
SCHMITZ A; SANKARANARAYANAN A; AZAM P; SCHMIDT-LASSEN K; HOMERICK D; HANSEL W; WULFF H: "Design of PAP-1, a selective small molecule Kvl.3 blocker, for the suppression of effector memory cells in autoimmune diseases", MOL. PHARMACOL., vol. 68, 2005, pages 1254 - 1270
SHIEH ET AL.: "Potassium Channels: Molecular Defects, Diseases, and Therapeutic Opportunities", PHARMACOL REV, vol. 52, no. 4, 2000, pages 557 - 594, XP002295931
VENNEKAMP J; WULFF H; BEETON C; CALABRESI PA; GRISSMER S; HANSEL W; CHANDY KG: "Kvl.3-blocking 5-phenylalkoxypsoralens: a new class of immunomodulators", MOL. PHARMACOL., vol. 65, 2004, pages 1364 - 74, XP002525944, DOI: doi:10.1124/mol.65.6.1364
WULFF H ET AL.: "Alkoxypsoralens, Novel Nonpeptide Blockers of Shaker-Type K+ Channels: Synthesis and Photoreactivity", J. MED. CHEM., vol. 41, 1998, pages 4542 - 4549, XP002133978, DOI: doi:10.1021/jm981032o
WULFF H; BEETON C; CHANDY KG: "Potassium channels as therapeutic targets for autoimmune disorders", CURR. OPIN. DRUG DIS., vol. 6, no. 5, 2003, pages 640 - 647
XIE M ET AL.: "Ion Channel Drug Discovery Expands into New Disease Areas", CURRENT DRUG DISCOVERY, 2004, pages 31 - 33

Cited By (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10689425B2 (en) 2008-03-27 2020-06-23 Purdue Research Foundation Collagen-binding synthetic peptidoglycans, preparation, and methods of use
US9512192B2 (en) 2008-03-27 2016-12-06 Purdue Research Foundation Collagen-binding synthetic peptidoglycans, preparation, and methods of use
US9217016B2 (en) 2011-05-24 2015-12-22 Symic Ip, Llc Hyaluronic acid-binding synthetic peptidoglycans, preparation, and methods of use
CN103732614B (zh) * 2011-05-24 2016-08-17 塞米克Ip有限公司 结合透明质酸的合成肽聚糖、制备和使用方法
EP3208278A1 (en) * 2011-05-24 2017-08-23 Symic IP, LLC Hyaluronic acid-binding synthetic peptidoglycans, preparation, and methods of use
EP2714718A4 (en) * 2011-05-24 2015-01-14 Symic Biomedical Inc HYALURONIC ACID BINDING SYNTHETIC PEPTIDOGLYCANES, THEIR PREPARATION AND METHOD FOR THEIR USE
US9200039B2 (en) 2013-03-15 2015-12-01 Symic Ip, Llc Extracellular matrix-binding synthetic peptidoglycans
US9872887B2 (en) 2013-03-15 2018-01-23 Purdue Research Foundation Extracellular matrix-binding synthetic peptidoglycans
US10772931B2 (en) 2014-04-25 2020-09-15 Purdue Research Foundation Collagen binding synthetic peptidoglycans for treatment of endothelial dysfunction
US20190256511A1 (en) * 2016-07-14 2019-08-22 Shanghai Meton Pharmaceutical Co., Ltd Iso-citrate dehydrogenase (idh) inhibitor
CN109641890A (zh) * 2016-07-14 2019-04-16 上海迈同生物科技有限公司 异柠檬酸脱氢酶(idh)抑制剂
US10752626B2 (en) * 2016-07-14 2020-08-25 Shanghai Meton Pharmaceutical Co., Ltd Iso-citrate dehydrogenase (IDH) inhibitor
WO2018010142A1 (en) * 2016-07-14 2018-01-18 Shanghai Meton Pharmaceutical Co., Ltd Iso-citrate dehydrogenase (idh) inhibitor
CN109641890B (zh) * 2016-07-14 2022-04-26 浙江迈同生物医药有限公司 异柠檬酸脱氢酶(idh)抑制剂
US11529424B2 (en) 2017-07-07 2022-12-20 Symic Holdings, Inc. Synthetic bioconjugates
WO2021068698A1 (en) 2019-10-12 2021-04-15 Shanghai Meton Pharmaceutical Co., Ltd Iso-citrate dehydrogenase (idh) inhibitor
CN114555597A (zh) * 2019-10-12 2022-05-27 浙江迈同生物医药有限公司 异柠檬酸脱氢酶（idh）抑制剂
CN114555597B (zh) * 2019-10-12 2024-06-04 浙江迈同生物医药有限公司 异柠檬酸脱氢酶（idh）抑制剂
US12441725B2 (en) 2019-10-12 2025-10-14 Zhejiang Meton Pharmaceutical Co., Ltd ISO-citrate dehydrogenase (IDH) inhibitor

Also Published As

Publication number Publication date
JP2012528839A (ja) 2012-11-15
US8399481B2 (en) 2013-03-19
JP5684800B2 (ja) 2015-03-18
GB0909671D0 (en) 2009-07-22
US20110136859A1 (en) 2011-06-09
EP2438044A1 (en) 2012-04-11
EP2438044B1 (en) 2019-01-23

Similar Documents

Publication Publication Date Title
EP2438044B1 (en) Compounds
EP2342177B1 (en) Novel potassium channel blockers
EP2344456B1 (en) Novel potassium channel blocker
US8372840B2 (en) Potassium channel blockers
CA3069720A1 (en) Carboxamides as modulators of sodium channels
EP0630373A1 (en) Indole derivatives as 5ht1c antagonists
CN112384500A (zh) 免疫调节剂及其组合物和制备方法
JP2007533635A (ja) バニロイド受容体リガンドおよび治療おけるこれらの使用
KR20040048984A (ko) 오피오이드 수용체 길항제로서의3-아자비사이클로[3.1.0]헥산 유도체
EP2438055B1 (en) Dihydroindole and tetrahydroisoquinoline derivatives useful as potassium channel inhibitors
RU2136678C1 (ru) Производные n-замещенного 3-азабицикло[3.2.0]гептана
AU2019339703B2 (en) Immunomodulators, compositions and methods there of
JP2001525398A (ja) 選択的β３アドレナリン作動性アゴニスト
EP1819672A1 (en) Indole-2-carboxylic acid amides
HK40049451A (en) Immunomodulator, composition and preparation method thereof
MXPA00005964A (en) Novel sulfonamide substituted chroman derivatives useful as beta-3 adrenoreceptor agonists

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10722754

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2012513673

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2010722754

Country of ref document: EP